Global First As Japan Starts iPS Cell Trial In Parkinson's
Executive Summary
Building on its national expertise in the area, Japan is starting the first clinical trial globally to assess the use of iPS-derived cells for the treatment of Parkinson’s disease.
You may also be interested in...
First iPS Cell Trial Underway But A Long Way To Go
Researchers in Japan have "dosed" the initial patient in the world's first clinical trial involving a regenerative therapy based on the country's flagship induced pluripotent stem (iPS) cell technology.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.